|
|
|
| Expression of NOLC1 gene in gastric cancer tissues and its effect on cisplatin resistance |
| ZHAO Shengsheng,LU Jianhua, LI Hongzheng, SUN Weijian. |
| Department of Gastrointestinal Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325088, China |
|
| Cite this article: |
|
ZHAO Shengsheng,LU Jianhua,LI Hongzheng, et al. Expression of NOLC1 gene in gastric cancer tissues and its effect on cisplatin resistance[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2024, 54(7): 583-588.
|
|
|
|
Abstract Objective: To investigate the expression of NOLC1 in gastric cancer and its correlation with cisplatin resistance. Methods: The Cancer Genome Atlas (TCGA) database was used to evaluate the expression
level of NOLC1, and Kaplan-Meier survival analysis was used to predict the prognostic value of NOLC1 in gastric cancer patients. The expression of NOLC1 in gastric cancer tissues was detected by immunohistochemistry.The cisplatin-resistant cells were induced by continuous addition of cisplatin at low concentration. The expression of NOLC1 in drug-resistant and sensitive cells was detected by immunofluorescence and Western blot. A stable NOLC1 knockdown gastric cancer cell line was constructed by lentivirus. Gastric cancer cells were treated with different concentrations of cisplatin for 24h. CCK-8 assay, colony formation assay, and flow cytometry were used to detect the effect of NOLC1 on cisplatin resistance of gastric cancer cells. Western blot was used to detect the expression level of apoptosis-related proteins induced by cisplatin after NOLC1 knockdown. Results: NOLC1 was highly expressed in gastric cancer tissues (P<0.05), which predicted poor prognosis (P<0.01). NOLC1 was highly expressed in cisplatin-resistant gastric cancer cell lines (P<0.01). After NOLC1 knockdown, cisplatin enhanced the killing ability and proliferation inhibition of gastric cancer cells (P<0.05), and the expression of apoptosis-related proteins such as Cl-Caspase3 and Cl-PARP was up-regulated (P<0.01).Conclusion: NOLC1 is highly expressed in gastric cancer and can promote the resistance of gastric cancer to cisplatin.
|
|
Received: 15 January 2024
|
| |
|
|
|
|
|
|
